Dianthus Therapeutics Inc. (DNTH) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Dianthus Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$82.31
+3.51% today
Market cap
$4.4B
Overall quality
34/100
Kronos AI 30-day
+14.3%
8 of 8 simulated paths end higher
Dianthus Therapeutics Inc. (DNTH) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $4.4B. It trades at $82.31, up 3.51% today. Its overall quality score is 34 out of 100, ranked against the whole US market. 14 analysts' average target of $140.33 implies +70.5% from today's price. Kronos AI's 30-day forecast is +14.3% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $140.33 |
| Low – high | $113.00 – $200.00 |
| Analysts | 14 |
| Upside to average | +70.5% |
Kronos AI 30-day forecast
| Expected close | $90.91 (+14.3%) |
| Likely range | +8.9% … +18.6% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 9 |
| Solvency | 56 |
| Growth | 36 |
| Overall | 34 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.